Science Explorer Back to mapMap

Most cited papers from Cleveland BioLabs (United States)

What are the most cited papers from Cleveland BioLabs (United States)?

The most cited paper from Cleveland BioLabs (United States) is "An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models" (Lyudmila G. Burdelya, Vadim I. Krivokrysenko, Thomas C. Tallant et al., 2008), with 707 citations. Next come "Structural Basis of TLR5-Flagellin Recognition and Signaling" (586) and "Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation" (329).

Showing 50 of 60 papers. Every paper with more than 26 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models Lyudmila G. Burdelya, Vadim I. Krivokrysenko, Thomas C. Tallant et al. · Science Open access 10 Apr 2008 707
2 Structural Basis of TLR5-Flagellin Recognition and Signaling Sung‐il Yoon, Oleg V. Kurnasov, Venkatesh Natarajan et al. · Science Open access 16 Feb 2012 586
3 Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation Evguenia Strom, Swati S. Sathe, Pavel G. Komarov et al. · Nature Chemical Biology 23 Jul 2006 329
4 Core circadian protein CLOCK is a positive regulator of NF-κB–mediated transcription Mary L. Spengler, Karen K. Kuropatwinski, Maria Comas et al. · Proceedings of the National Academy of Sciences Open access 15 Aug 2012 325
5 Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors Katerina V. Gurova, Jason E. Hill, Canhui Guo et al. · Proceedings of the National Academy of Sciences Open access 15 Nov 2005 266
6 Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT Alexander V. Gasparian, Catherine A. Burkhart, Andrei A. Purmal et al. · Science Translational Medicine Open access 10 Aug 2011 248
7 p53 is a suppressor of inflammatory response in mice Elena A. Komarova, Vadim I. Krivokrysenko, Kaihua Wang et al. · The FASEB Journal 5 Apr 2005 246
8 Prospective therapeutic applications of p53 inhibitors Andrei V. Gudkov, Elena A. Komarova · Biochemical and Biophysical Research Communications 11 Apr 2005 141
9 A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation Alexander D. Boiko, Sarah Porteous, Olga V. Razorenova et al. · Genes & Development Open access 15 Jan 2006 140
10 Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist Lyudmila G. Burdelya et al. · Proceedings of the National Academy of Sciences Open access 29 Apr 2013 121
11 Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma Catherine A. Burkhart, Fujiko Watt, Jayne E. Murray et al. · Cancer Research Open access 4 Aug 2009 120
12 Association of Mycoplasma hominis infection with prostate cancer Yulia A. Barykova, Denis Y. Logunov, М. М. Шмаров et al. · Oncotarget Open access 4 Apr 2011 119
13 Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy Lyudmila G. Burdelya, Anatoli S. Gleiberman, Ilia A. Toshkov et al. · International Journal of Radiation Oncology*Biology*Physics Open access 17 Oct 2011 118
14 Pathologies Associated with the p53 Response Andrei V. Gudkov, Elena A. Komarova · Cold Spring Harbor Perspectives in Biology Open access 7 Apr 2010 117
15 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways Chuanbin Guo, A. V. Gasparian, Zhengping Zhuang et al. · Oncogene 12 Jan 2009 116
16 New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis Maria Comas, Ilia A. Toshkov, Karen K. Kuropatwinski et al. · Aging Open access 29 Oct 2012 116
17 Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure Vadim I. Krivokrysenko, Alexander N. Shakhov, Vijay Kumar Singh et al. · Journal of Pharmacology and Experimental Therapeutics Open access 27 Jul 2012 113
18 Essential genes on metabolic maps Svetlana Gerdes, Robert Alan Edwards, Michael Kubal et al. · Current Opinion in Biotechnology Review 19 Sep 2006 112
19 Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8 + T-cell axis Craig M. Brackett, Bojidar Kojouharov, Jean M. Veith et al. · Proceedings of the National Academy of Sciences Open access Feb 2016 100
20 Cooperative regulation in development by SMRT and FOXP1 Kristen Jepsen, Anatoli S. Gleiberman, Can Shi et al. · Genes & Development Open access 15 Mar 2008 99
21 MULTIPLE PARAMETER RADIATION INJURY ASSESSMENT USING A NONHUMAN PRIMATE RADIATION MODEL—BIODOSIMETRY APPLICATIONS William F. Blakely, Natalia I. Ossetrova, Mark H. Whitnall et al. · Health Physics 6 Jan 2010 94
22 Validation of a Novel Immunoassay for the Detection of Synthetic Cannabinoids and Metabolites in Urine Specimens A. Arntson, Bill Ofsa, Danny J. Lancaster et al. · Journal of Analytical Toxicology 26 Apr 2013 93
23 Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib Nickolay S. Neznanov, Andrei P. Komarov, Lubov Neznanova et al. · Oncotarget Open access 27 Mar 2011 92
24 Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models Josephine Kam Tai Dermawan, Masahiro Hitomi, Daniel J. Silver et al. · Cancer Research Open access 26 Feb 2016 79
25 Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation Denis Y. Logunov, D. V. Scheblyakov, Olga V. Zubkova et al. · Oncogene Open access 14 Apr 2008 79
26 Prevention and Mitigation of Acute Radiation Syndrome in Mice by Synthetic Lipopeptide Agonists of Toll-Like Receptor 2 (TLR2) Alexander N. Shakhov, Vijay Kumar Singh, Frederick Bone et al. · PLoS ONE Open access 27 Mar 2012 73
27 CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide ofMycoplasma arginini, as a Novel Radiation Countermeasure Vijay Kumar Singh, Elizabeth J. Ducey, Oluseyi O. Fatanmi et al. · Radiation Research May 2012 72
28 Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma Tara A. Barone, Catherine A. Burkhart, Alfiya F. Safina et al. · Neuro-Oncology Open access Jul 2016 68
29 Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas Julia V. Kichina, Marija Zeremski, L Aris et al. · Oncogene 19 Sep 2005 66
30 Association of Serum Magnesium on Mortality in Patients Admitted to the Intensive Cardiac Care Unit Niyada Naksuk, Tiffany Ying Hu, Chayakrit Krittanawong et al. · The American Journal of Medicine Open access 15 Sep 2016 65
31 p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma Chengyuan Xue, Michelle Haber, Claudia L. Flemming et al. · Cancer Research Nov 2007 64
32 The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates Vadim I. Krivokrysenko, Ilia A. Toshkov, Anatoli S. Gleiberman et al. · PLoS ONE Open access 14 Sep 2015 63
33 Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients Allen R. Nissenson, Jeffrey S. Berns, Paul G. Sakiewicz et al. · American Journal of Kidney Diseases Aug 2003 62
34 Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications Nickolay S. Neznanov, Anton V. Gorbachev, Lubov Neznanova et al. · Cell Cycle Open access Dec 2009 59
35 Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2 / neu Transgenic Mice Igor E. Koman, Mairead Commane, Geraldine Paszkiewicz et al. · Cancer Prevention Research 12 Jun 2012 58
36 Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice Lyudmila G. Burdelya, Elena A. Komarova, Jason E. Hill et al. · Cancer Research Open access Oct 2006 55
37 Tissue-Specific Changes in Molecular Clocks During the Transition from Pregnancy to Lactation in Mice1 Theresa Casey, Jennifer S. Crodian, Emily C. Erickson et al. · Biology of Reproduction Open access 24 Apr 2014 50
38 Assessment of stored red blood cells through lab-on-a-chip technologies for precision transfusion medicine Ziya Işıksaçan, Angelo D’Alessandro, Susan M. Wolf et al. · Proceedings of the National Academy of Sciences Open access 26 Jul 2023 48
39 The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism Hua Yang, Craig M. Brackett, Vanessa Marie Morales-Tirado et al. · Oncotarget Open access 8 Dec 2015 47
40 Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication Nickolay S. Neznanov, Eugenia M. Dragunsky, Konstantin M. Chumakov et al. · PLoS ONE Open access Apr 2008 47
41 Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy Vadim L. Mett, Elena A. Komarova, Kristopher M. Greene et al. · Oncogene Open access 2 Oct 2017 46
42 Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses Amir I. Tukhvatulin, Alina Sh. Dzharullaeva, Natalia M. Tukhvatulina et al. · PLoS ONE Open access 17 May 2016 44
43 Targeting transcription factor NFκB: comparative analysis of proteasome and IKK inhibitors Alexander V. Gasparian, Olga A. Guryanova, Dmitry V. Chebotaev et al. · Cell Cycle Open access 15 May 2009 44
44 Herpes simplex viruses: Discrimination of types and correlation between different characteristics Gordon Plummer, Clyde R. Goodheart, Masakazu Miyagi et al. · Virology Jul 1974 44
45 Deficiency in PER proteins has no effect on the rate of spontaneous and radiation-induced carcinogenesis Marina P. Antoch, Ilia A. Toshkov, Karen K. Kuropatwinski et al. · Cell Cycle Open access 25 Oct 2013 43
46 Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection Amir I. Tukhvatulin, Ilya I. Gitlin, Dmitry V. Shcheblyakov et al. · Infection and Immunity Open access 30 Jul 2013 42
47 A TLR5 Agonist Inhibits Acute Renal Ischemic Failure Nobuyuki Fukuzawa, Marianne Petro, William M. Baldwin et al. · The Journal of Immunology Open access 3 Sep 2011 41
48 A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice Katerina I. Leonova, Jelena Shneyder, Marina P. Antoch et al. · Cell Cycle Open access Apr 2010 41
49 Equine Herpesviruses: Antigenic Relationships and Deoxyribonucleic Acid Densities Gordon Plummer, Clyde R. Goodheart, Michael J. Studdert · Infection and Immunity Open access Oct 1973 40
50 In vitro neoplastic transformation of Syrian hamster cells by lead acetate and its relevance to environmental carcinogenesis Joseph A. DiPaolo, Richard L. Nelson, B. C. Casto · British Journal of Cancer Open access Sep 1978 39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.